-
- EXPLORAR
-
-
Global Array Instruments Market Expected to Reach USD 11.9 Billion by 2031 as Demand Increases in Research and Clinical Genomics

[Boston, 4th June 2025] – Clearview Market Insights (CVMI) projects that the global array instruments market will more than double from USD 5.4 billion in 2024 to USD 11.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 12.1 percent. This growth is driven by increasing demand for personalized medicine, multiplexed diagnostic platforms, and high-throughput drug screening tools across both developed and emerging economies.
“Array-based technologies are evolving from basic gene expression tools into powerful multi-omics platforms that integrate genomic, transcriptomic, and proteomic data for precision diagnostics and therapeutics,” said Dr. Mira Patel, genomics innovation lead at CVMI. “This shift is unlocking transformative potential in oncology, neurology, rare disease research, and even agricultural applications.”
Request Sample @ https://clearviewmarketinsights.com/report-details/global-array-instruments-market/
Key Numbers
- 2024 Market Value: USD 5.4 billion
- 2031 Market Value: USD 11.9 billion
- Seven-Year CAGR: 12.1 percent
- DNA Arrays Share (2024): 38%
- North America Share: 42%, Asia-Pacific fastest-growing region
Market Drivers
- Precision medicine and population-scale screening
- Expansion of biomarker discovery programs
- Multi-omics platform integration
- Technological miniaturization and AI analytics
- Increased funding from NIH, Horizon Europe, and Asian genomics initiatives
Company Highlights
- Agilent launched high-density rare-variant arrays for translational genomics.
- Illumina deepened partnerships with government-funded genetic screening projects.
- Thermo Fisher connected proteomic array data to cloud analytics suites for clinical trials.
- Arrayit brought DTC testing kits for protein biomarkers to the consumer market.
- Bio-Rad introduced ELISA-array hybrids for autoimmune disease detection.
Regional Highlights
- North America: Sustained investment in genomics infrastructure, academic trials, and diagnostic innovation.
- Asia-Pacific: Government-led genome sequencing initiatives drive rapid adoption.
- Europe: IVDR compliance spurs demand for certified clinical-grade array systems.
- LATAM & MEA: Market expansion supported by public-private genomics collaborations and global health donors.
2024–2025 Milestones
Quarter |
Event |
Outcome |
Q1 2024 |
Agilent launches G3 HD arrays |
Enables 50% higher resolution gene expression profiling |
Q2 2024 |
Thermo Fisher integrates array data into oncology cloud suite |
Accelerates patient stratification in trials |
Q3 2024 |
Illumina signs regional genomics pact in Southeast Asia |
Adds 5 million samples to population genomics pipeline |
Q1 2025 |
Bio-Rad introduces dual-modality ELISA-array systems |
Improves throughput in autoimmune diagnostics |
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369